From Wikipedia, the free encyclopedia
|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||146.44 kg/mol|
|(what is this?)|
Mogamulizumab (USAN; trade name Poteligeo) is a humanized monoclonal antibody targeting CC chemokine receptor 4 (CCR4). It was approved in Japan in 2012 for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma.
- Subramaniam, J; Whiteside G; McKeage K; Croxtall J (18 June 2012). "Mogamulizumab: First Global Approval". Drugs. 72 (9): 1293–1298. PMID 22686619. doi:10.2165/11631090-000000000-00000. Retrieved 10 September 2012.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Mogamulizumab" (PDF). American Medical Association.
- "Kyowa Hakko Kirin R&D Pipeline" (PDF). Kyowa Hakko Kirin. Retrieved 10 September 2012.
- A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|